Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial of oxaliplatin and fluorouracil (5FU) for recurrent ovarian cancer
This trial looked at 2 chemotherapy drugs called oxaliplatin and 5 fluorouracil (5FU) for ovarian cancer that had come back (recurred) after treatment.
When this trial was done, doctors usually used 2
This trial looked at a newer platinum chemotherapy drug called oxaliplatin in combination with fluorouracil (5FU) and a vitamin called folinic acid (Leucovorin). It recruited women whose cancer had already come back after treatment with cisplatin or carboplatin.
The aims of the trial were to find out
- How well treatment works
- More about the side effects
Summary of results
The trial team found that oxaliplatin and fluorouracil helped a few women with advanced ovarian cancer.
This was a small trial and recruited 27 women with advanced ovarian cancer that had come back after platinum chemotherapy.
Everybody had oxaliplatin and fluorouracil (5FU) chemotherapy. Most women had between 3 and 6 cycles of treatment.
The researchers analysed the results in 2004. They had the results for 25 women. They found that
- The cancer went away in 3 women – doctors call this a ‘complete response’
- The cancer slowed or stopped growing in 3 women – doctors call this a ‘partial response’
- The cancer continued to grow in 19 women
The researchers found that oxaliplatin and fluorouracil was safe to use and helped a few women whose ovarian cancer had come back after earlier platinum chemotherapy.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Kenneth O’Byrne
University Hospitals of Leicester NHS Trust